TG Therapeutics (TGTX) reported $240.34 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 70.3%. EPS of $0.05 for the same period compares to $0.17 a year ago.
The reported revenue represents a surprise of +4.08% over the Zacks Consensus Estimate of $230.91 million. With the consensus EPS estimate being $0.41, the EPS surprise was -87.81%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how TG Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
-
Revenue- Product revenue, net: $235.79 million versus the three-analyst average estimate of $227.02 million. The reported number represents a year-over-year change of +69.8%.
-
Revenue- License, milestone, royalty and other: $4.54 million versus $3.88 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +97% change.
-
Product revenue- BRIUMVI - U.S.: $227.7 million compared to the $221.92 million average estimate based on two analysts.
-
Product revenue- BRIUMVI - International (ex-U.S.): $8.1 million compared to the $6.62 million average estimate based on two analysts.
View all Key Company Metrics for TG Therapeutics here>>>
Shares of TG Therapeutics have returned -2.4% over the past month versus the Zacks S&P 500 composite's +0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
